Crexont (Carbidopa/Levodopa) Patent Expiration, LOE Window & CMS Spending
Crexont (Carbidopa/Levodopa) by Amneal Pharmaceuticals: FDA Orange Book LOE 2041-12-21, 18 AB generics, $2.6M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amneal Pharmaceuticals |
| FDA Application & Pathway | N217186 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2041-12-21 |
| Orange Book Patents (*PED Extensions) | 30 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 18 |
| 2024 CMS Total Public Spend | $2.6M |
| 2024 Medicare Part D Spend | $2.5M |
| 2024 Medicaid Spend | $60K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |